Velcade, Trisenox, Vitamin C and Melphalan for Myeloma Patients

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

June 30, 2006

Primary Completion Date

December 31, 2008

Study Completion Date

December 31, 2008

Conditions
Myeloma
Interventions
DRUG

Trisenox (Arsenic Trioxide)

0.25 mg/kg by vein over 2 hours, once a day for 7 days (Days -9 to -3).

DRUG

Velcade (Bortezomib)

"Arm 1 (Level 1):~1.0 mg/m\^2 intravenous (IV) push on Days -9, -6, and -3. An IV push takes a short period of time (less than 1 minute).~Arm 2 (Level 2):~1.5 mg/m\^2 intravenous (IV) push on Days -9, -6, and -3. An IV push takes a short period of time (less than 1 minute)."

DRUG

Melphalan

100 mg/m2 by vein days -4,-3, over 30 minutes

DRUG

Vitamin C (Ascorbic Acid)

1000 mg once a day through the vein for 7 days.

Trial Locations (1)

77030

UT MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Cephalon

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER

NCT00469209 - Velcade, Trisenox, Vitamin C and Melphalan for Myeloma Patients | Biotech Hunter | Biotech Hunter